Epinephrine Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 30 pharmaceutical companies such as PIERREL, HOSPIRA, SEPTODONT INC and others. It is marketed under 17 brand names, including ORABLOC, ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE and others. Available in 33 different strengths, such as 4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML), 4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML), 4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML) and others, and administered through 8 routes including INJECTABLE;INJECTION, SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS, SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS and others.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 30 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"71722","ingredient":"EPINEPHRINE","trade_name":"AUVI-Q","family_id":"a9d2ce044fe34ef8b2aa","publication_number":"US10335549B2","cleaned_patent_number":"10335549","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-04-30","publication_date":"2019-07-02","legal_status":"Patented case"} US10335549B2 Formulation 02 Jul, 2019 Patented case 30 Apr, 2025
{"application_id":"62207","ingredient":"EPINEPHRINE","trade_name":"EPIPEN","family_id":"ca6a8d449c50465a82d1","publication_number":"US9586010B2","cleaned_patent_number":"9586010","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-09-11","publication_date":"2017-03-07","legal_status":"Granted"} US9586010B2 Formulation 07 Mar, 2017 Granted 11 Sep, 2025
{"application_id":"62160","ingredient":"EPINEPHRINE","trade_name":"EPIPEN","family_id":"ca6a8d449c50465a82d1","publication_number":"US8870827B2","cleaned_patent_number":"8870827","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-09-11","publication_date":"2014-10-28","legal_status":"Granted"} US8870827B2 Formulation 28 Oct, 2014 Granted 11 Sep, 2025
{"application_id":"62205","ingredient":"EPINEPHRINE","trade_name":"EPIPEN","family_id":"ca6a8d449c50465a82d1","publication_number":"US7794432B2","cleaned_patent_number":"7794432","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-09-11","publication_date":"2010-09-14","legal_status":"Granted"} US7794432B2 Formulation 14 Sep, 2010 Granted 11 Sep, 2025
{"application_id":"62206","ingredient":"EPINEPHRINE","trade_name":"EPIPEN","family_id":"ca6a8d449c50465a82d1","publication_number":"US8048035B2","cleaned_patent_number":"8048035","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-09-11","publication_date":"2011-11-01","legal_status":"Granted"} US8048035B2 Formulation 01 Nov, 2011 Granted 11 Sep, 2025
{"application_id":"62204","ingredient":"EPINEPHRINE","trade_name":"EPIPEN","family_id":"ca6a8d449c50465a82d1","publication_number":"US7449012B2","cleaned_patent_number":"7449012","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-09-11","publication_date":"2008-11-11","legal_status":"Granted"} US7449012B2 Formulation 11 Nov, 2008 Granted 11 Sep, 2025
{"application_id":"43359","ingredient":"EPINEPHRINE","trade_name":"PRIMATENE MIST","family_id":"73ef5cea5e7342bb9241","publication_number":"US8367734B1","cleaned_patent_number":"8367734","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-01-26","publication_date":"2013-02-05","legal_status":"Granted"} US8367734B2 Formulation 05 Feb, 2013 Granted 26 Jan, 2026
{"application_id":"71734","ingredient":"EPINEPHRINE","trade_name":"AUVI-Q","family_id":"a9d2ce044fe34ef8b2aa","publication_number":"US11590286B2","cleaned_patent_number":"11590286","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-12-12","publication_date":"2023-02-28","legal_status":"Granted"} US11590286B2 Formulation 28 Feb, 2023 Granted 12 Dec, 2026
{"application_id":"71685","ingredient":"EPINEPHRINE","trade_name":"AUVI-Q","family_id":"a9d2ce044fe34ef8b2aa","publication_number":"US8206360B2","cleaned_patent_number":"8206360","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-02-27","publication_date":"2012-06-26","legal_status":"Granted"} US8206360B2 Formulation 26 Jun, 2012 Granted 27 Feb, 2027
{"application_id":"71679","ingredient":"EPINEPHRINE","trade_name":"AUVI-Q","family_id":"a9d2ce044fe34ef8b2aa","publication_number":"US7947017B2","cleaned_patent_number":"7947017","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-03-12","publication_date":"2011-05-24","legal_status":"Patented case"} US7947017B2 Formulation 24 May, 2011 Patented case 12 Mar, 2028
{"application_id":"71687","ingredient":"EPINEPHRINE","trade_name":"AUVI-Q","family_id":"a9d2ce044fe34ef8b2aa","publication_number":"US8231573B2","cleaned_patent_number":"8231573","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-11-25","publication_date":"2012-07-31","legal_status":"Patented case"} US8231573B2 Formulation 31 Jul, 2012 Patented case 25 Nov, 2028
{"application_id":"71686","ingredient":"EPINEPHRINE","trade_name":"AUVI-Q","family_id":"a9d2ce044fe34ef8b2aa","publication_number":"US8226610B2","cleaned_patent_number":"8226610","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-04-10","publication_date":"2012-07-24","legal_status":"Granted"} US8226610B2 Formulation 24 Jul, 2012 Granted 10 Apr, 2029
{"application_id":"71681","ingredient":"EPINEPHRINE","trade_name":"AUVI-Q","family_id":"a9d2ce044fe34ef8b2aa","publication_number":"US8021344B2","cleaned_patent_number":"8021344","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-11-02","publication_date":"2011-09-20","legal_status":"Granted"} US8021344B2 Formulation 20 Sep, 2011 Granted 02 Nov, 2029
{"application_id":"71588","ingredient":"EPINEPHRINE","trade_name":"EPINEPHRINE","family_id":"55ce1d655f894bee9101","publication_number":"US10004700B1","cleaned_patent_number":"10004700","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-08-14","publication_date":"2018-06-26","legal_status":"Granted"} US10004700B2 Formulation 26 Jun, 2018 Granted 14 Aug, 2034
{"application_id":"71589","ingredient":"EPINEPHRINE","trade_name":"EPINEPHRINE","family_id":"55ce1d655f894bee9101","publication_number":"US10039728B1","cleaned_patent_number":"10039728","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-08-14","publication_date":"2018-08-07","legal_status":"Granted"} US10039728B2 07 Aug, 2018 Granted 14 Aug, 2034
{"application_id":"71587","ingredient":"EPINEPHRINE","trade_name":"EPINEPHRINE","family_id":"55ce1d655f894bee9101","publication_number":"US9283197B1","cleaned_patent_number":"9283197","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-08-15","publication_date":"2016-03-15","legal_status":"Granted"} US9283197B2 Formulation 15 Mar, 2016 Granted 15 Aug, 2034
{"application_id":"164434","ingredient":"NOREPINEPHRINE BITARTRATE","trade_name":"NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE","family_id":"","publication_number":"USRE49443E","cleaned_patent_number":"RE49443","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-02-26","publication_date":"2023-03-07","legal_status":"Granted"} USRE49443E1 Formulation 07 Mar, 2023 Granted 26 Feb, 2035
{"application_id":"164432","ingredient":"NOREPINEPHRINE BITARTRATE","trade_name":"NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE","family_id":"","publication_number":"USRE49422E","cleaned_patent_number":"RE49422","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-02-26","publication_date":"2023-02-21","legal_status":"Granted"} USRE49422E1 Formulation 21 Feb, 2023 Granted 26 Feb, 2035
{"application_id":"164433","ingredient":"NOREPINEPHRINE BITARTRATE","trade_name":"NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE","family_id":"","publication_number":"US10251848B2","cleaned_patent_number":"10251848","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-02-26","publication_date":"2019-04-09","legal_status":"Granted"} US10251848B2 Formulation 09 Apr, 2019 Granted 26 Feb, 2035
{"application_id":"71571","ingredient":"EPINEPHRINE","trade_name":"ADRENALIN","family_id":"100c1a703d704dd9b0ba","publication_number":"US9295657B1","cleaned_patent_number":"9295657","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-03-13","publication_date":"2016-03-29","legal_status":"Patented case"} US9295657B2 29 Mar, 2016 Patented case 13 Mar, 2035
{"application_id":"71578","ingredient":"EPINEPHRINE","trade_name":"ADRENALIN","family_id":"100c1a703d704dd9b0ba","publication_number":"US9119876B1","cleaned_patent_number":"9119876","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-03-13","publication_date":"2015-09-01","legal_status":"Granted"} US9119876B2 Formulation 01 Sep, 2015 Granted 13 Mar, 2035
{"application_id":"71579","ingredient":"EPINEPHRINE","trade_name":"ADRENALIN","family_id":"100c1a703d704dd9b0ba","publication_number":"US10130592B2","cleaned_patent_number":"10130592","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-03-13","publication_date":"2018-11-20","legal_status":"Patented case"} US10130592B2 Formulation 20 Nov, 2018 Patented case 13 Mar, 2035
{"application_id":"164431","ingredient":"EPINEPHRINE","trade_name":"ADRENALIN","family_id":"100c1a703d704dd9b0ba","publication_number":"US12280024B2","cleaned_patent_number":"12280024","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-03-13","publication_date":"2025-04-22","legal_status":"Granted"} US12280024B2 Formulation 22 Apr, 2025 Granted 13 Mar, 2035
{"application_id":"71812","ingredient":"EPINEPHRINE","trade_name":"SYMJEPI","family_id":"0bd7b42ae45f43fd946d","publication_number":"US11141540B2","cleaned_patent_number":"11141540","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-10-20","publication_date":"2021-10-12","legal_status":"Granted"} US11141540B2 Formulation 12 Oct, 2021 Granted 20 Oct, 2036
{"application_id":"71755","ingredient":"EPINEPHRINE","trade_name":"AUVI-Q","family_id":"6fd6ee24218f42f68790","publication_number":"US10842938B2","cleaned_patent_number":"10842938","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-12-21","publication_date":"2020-11-24","legal_status":"Granted"} US10842938B2 Formulation 24 Nov, 2020 Granted 21 Dec, 2037
{"application_id":"120806","ingredient":"EPINEPHRINE","trade_name":"AUVI-Q","family_id":"6fd6ee24218f42f68790","publication_number":"US11771830B2","cleaned_patent_number":"11771830","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-12-21","publication_date":"2023-10-03","legal_status":"Granted"} US11771830B2 Formulation 03 Oct, 2023 Granted 21 Dec, 2037
{"application_id":"71750","ingredient":"EPINEPHRINE","trade_name":"AUVI-Q","family_id":"6fd6ee24218f42f68790","publication_number":"US10688244B2","cleaned_patent_number":"10688244","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-12-21","publication_date":"2020-06-23","legal_status":"Patented case"} US10688244B2 Formulation 23 Jun, 2020 Patented case 21 Dec, 2037
{"application_id":"108551","ingredient":"NOREPINEPHRINE BITARTRATE","trade_name":"NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE","family_id":"78b0053c851847818923","publication_number":"US11413259B2","cleaned_patent_number":"11413259","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-01-30","publication_date":"2022-08-16","legal_status":"Granted"} US11413259B2 Formulation 16 Aug, 2022 Granted 30 Jan, 2038
{"application_id":"108557","ingredient":"NOREPINEPHRINE BITARTRATE","trade_name":"NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE","family_id":"78b0053c851847818923","publication_number":"US10568850B2","cleaned_patent_number":"10568850","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-01-30","publication_date":"2020-02-25","legal_status":"Granted"} US10568850B2 Formulation 25 Feb, 2020 Granted 30 Jan, 2038
{"application_id":"108555","ingredient":"NOREPINEPHRINE BITARTRATE","trade_name":"NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE","family_id":"78b0053c851847818923","publication_number":"US10420735B2","cleaned_patent_number":"10420735","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-01-30","publication_date":"2019-09-24","legal_status":"Granted"} US10420735B2 Formulation 24 Sep, 2019 Granted 30 Jan, 2038
{"application_id":"108554","ingredient":"NOREPINEPHRINE BITARTRATE","trade_name":"NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE","family_id":"78b0053c851847818923","publication_number":"US10226436B2","cleaned_patent_number":"10226436","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-01-30","publication_date":"2019-03-12","legal_status":"Granted"} US10226436B2 Formulation 12 Mar, 2019 Granted 30 Jan, 2038
{"application_id":"111794","ingredient":"NOREPINEPHRINE BITARTRATE","trade_name":"NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE","family_id":"0b697d9d56d046be8f53","publication_number":"US11602508B2","cleaned_patent_number":"11602508","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-01-30","publication_date":"2023-03-14","legal_status":"Granted"} US11602508B2 Formulation 14 Mar, 2023 Granted 30 Jan, 2038
{"application_id":"111795","ingredient":"NOREPINEPHRINE BITARTRATE","trade_name":"NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE","family_id":"0b697d9d56d046be8f53","publication_number":"US2022409558A1","cleaned_patent_number":"12245996","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-01-30","publication_date":"2022-12-29","legal_status":"Pending"} US12245996B2 Formulation 29 Dec, 2022 Pending 30 Jan, 2038
{"application_id":"108553","ingredient":"NOREPINEPHRINE BITARTRATE","trade_name":"NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE","family_id":"78b0053c851847818923","publication_number":"US10159657B2","cleaned_patent_number":"10159657","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-01-30","publication_date":"2018-12-25","legal_status":"Granted"} US10159657B2 Formulation 25 Dec, 2018 Granted 30 Jan, 2038
{"application_id":"81759","ingredient":"EPINEPHRINE","trade_name":"NEFFY","family_id":"6c56d927c80142009b08","publication_number":"US10576156B2","cleaned_patent_number":"10576156","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-02-06","publication_date":"2020-03-03","legal_status":"Granted"} US10576156B2 Formulation 03 Mar, 2020 Granted 06 Feb, 2038
{"application_id":"81761","ingredient":"EPINEPHRINE","trade_name":"NEFFY","family_id":"6c56d927c80142009b08","publication_number":"US11173209B2","cleaned_patent_number":"11173209","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-02-06","publication_date":"2021-11-16","legal_status":"Granted"} US11173209B2 16 Nov, 2021 Granted 06 Feb, 2038
{"application_id":"242146","ingredient":"EPINEPHRINE","trade_name":"NEFFY","family_id":"","publication_number":"US12324838B2","cleaned_patent_number":"12324838","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-02-06","publication_date":"2025-06-10","legal_status":"Granted"} US12324838B2 Formulation 10 Jun, 2025 Granted 06 Feb, 2039
{"application_id":"81762","ingredient":"EPINEPHRINE","trade_name":"NEFFY","family_id":"6c56d927c80142009b08","publication_number":"US11191838B2","cleaned_patent_number":"11191838","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-02-06","publication_date":"2021-12-07","legal_status":"Granted"} US11191838B2 Formulation 07 Dec, 2021 Granted 06 Feb, 2039
{"application_id":"130719","ingredient":"EPINEPHRINE","trade_name":"NEFFY","family_id":"","publication_number":"US11717571B2","cleaned_patent_number":"11717571","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-02-06","publication_date":"2023-08-08","legal_status":"Granted"} US11717571B2 08 Aug, 2023 Granted 06 Feb, 2039
{"application_id":"81779","ingredient":"EPINEPHRINE","trade_name":"NEFFY","family_id":"6c56d927c80142009b08","publication_number":"US20210361770A1","cleaned_patent_number":"11744895","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-02-06","publication_date":"2021-11-25","legal_status":"Granted"} US11744895B2 25 Nov, 2021 Granted 06 Feb, 2039
{"application_id":"130718","ingredient":"EPINEPHRINE","trade_name":"NEFFY","family_id":"","publication_number":"US11918655B2","cleaned_patent_number":"11918655","drug_product_flag":"-, Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-02-06","publication_date":"2024-03-05","legal_status":"Granted"} US11918655B2 05 Mar, 2024 Granted 06 Feb, 2039
{"application_id":"81760","ingredient":"EPINEPHRINE","trade_name":"NEFFY","family_id":"6c56d927c80142009b08","publication_number":"US10682414B2","cleaned_patent_number":"10682414","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-02-06","publication_date":"2020-06-16","legal_status":"Granted"} US10682414B2 16 Jun, 2020 Granted 06 Feb, 2039
{"application_id":"112680","ingredient":"EPINEPHRINE","trade_name":"ADRENALIN","family_id":"dd4b36f22b72414d9dba","publication_number":"US2022110891A1","cleaned_patent_number":"12133837","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-03-21","publication_date":"2022-04-14","legal_status":"Pending"} US12133837B2 Formulation 14 Apr, 2022 Pending 21 Mar, 2039
{"application_id":"112675","ingredient":"EPINEPHRINE","trade_name":"ADRENALIN","family_id":"dd4b36f22b72414d9dba","publication_number":"US11083698B2","cleaned_patent_number":"11083698","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-03-21","publication_date":"2021-08-10","legal_status":"Granted"} US11083698B2 10 Aug, 2021 Granted 21 Mar, 2039
{"application_id":"112677","ingredient":"EPINEPHRINE","trade_name":"ADRENALIN","family_id":"dd4b36f22b72414d9dba","publication_number":"US10653646B2","cleaned_patent_number":"10653646","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-03-21","publication_date":"2020-05-19","legal_status":"Granted"} US10653646B2 Formulation 19 May, 2020 Granted 21 Mar, 2039
{"application_id":"112679","ingredient":"EPINEPHRINE","trade_name":"ADRENALIN","family_id":"dd4b36f22b72414d9dba","publication_number":"US11207280B2","cleaned_patent_number":"11207280","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-03-21","publication_date":"2021-12-28","legal_status":"Granted"} US11207280B2 Formulation 28 Dec, 2021 Granted 21 Mar, 2039
{"application_id":"108108","ingredient":"NOREPINEPHRINE BITARTRATE","trade_name":"NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE","family_id":"fb1a1ef4ff6f406a946d","publication_number":"US10888534B2","cleaned_patent_number":"10888534","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-04-26","publication_date":"2021-01-12","legal_status":"Granted"} US10888534B2 Formulation 12 Jan, 2021 Granted 26 Apr, 2039
{"application_id":"130705","ingredient":"NOREPINEPHRINE BITARTRATE","trade_name":"NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE","family_id":"","publication_number":"US12097170B2","cleaned_patent_number":"12097170","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2041-03-08","publication_date":"2024-09-24","legal_status":"Granted"} US12097170B2 Formulation 24 Sep, 2024 Granted 08 Mar, 2041
{"application_id":"242127","ingredient":"NOREPINEPHRINE BITARTRATE","trade_name":"NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE","family_id":"","publication_number":"US12290494B2","cleaned_patent_number":"12290494","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2041-03-08","publication_date":"2025-05-06","legal_status":"Granted"} US12290494B2 Formulation 06 May, 2025 Granted 08 Mar, 2041

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Epinephrine

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.